9月8日 - ** 总部位于加利福尼亚州的药物开发商Ideaya BiosciencesIDYA.O股价盘前上涨12%至30.42美元
** 该公司称，在一项中期试验中，其实验性药物darovasertib在放射治疗前缩小眼部肿瘤的大小方面显示出疗效，这种罕见的眼癌被称为新辅助葡萄膜黑色素瘤（neoadjuvant uveal melanoma）。
** IDYA 公司称，其药物还降低了患者治疗后失明的长期风险
** 该药于 2025 年 3 月获得美国食品及药物管理局的突破性疗法标签
** 截至上次收盘，该公司股价年累计上涨 5.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.